

PHARMING GROUP N.V.

ISIN: NL0010391025 WKN: 518940 Asset Class: **Stock**

Company

2024/08/07 17:35:28



Price

0.74 EUR

Difference ▲ 3.28%(0.02)



Contact Details

PHARMING GROUP NV Tel: +31-71-524-74-00
 -- Fax: +
 Darwinweg 24 Web: <http://www.pharming.com>
 2333 CR Leiden E-mail: info@pharming.com

Company Profile

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following segments: RUCONEST®, Joenja®, Europe, and Rest of the World. The company was founded on November 11, 1988, and is headquartered in Leiden, the Netherlands.

Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures | 2023 | | 2022 | | 2021 | |
|---------------------------------------|-------------|------------------------|-------------|------------------------|-------------|------------------------|
| | Assets | Liabilities and equity | Assets | Liabilities and equity | Assets | Liabilities and equity |
| Current assets | 286,373,000 | | 260,014,000 | | 219,349,000 | |
| Common stock capital | | 6,942,000 | | 7,035,000 | | 6,532,000 |
| Fixed assets | 139,966,000 | | 144,797,000 | | 135,138,000 | |
| Equity capital of a company | | 198,054,000 | | 191,743,000 | | 169,641,000 |
| Cash and cash equivalents | 55,891,000 | | 194,476,000 | | 168,968,000 | |
| Accrued liabilities | | 0 | | 0 | | 0 |
| Other assets | - | | - | | - | |
| Current liabilities | | 70,581,000 | | 55,936,000 | | 41,128,000 |
| Prepayments and accrued income | - | | - | | - | |
| Non-current liabilities | | 157,703,000 | | 157,131,000 | | 143,718,000 |
| Different income | | - | | - | | - |
| Other liabilities | | 0 | | 0 | | 145,000 |
| Total assets | 426,339,000 | 426,339,000 | 404,811,000 | 404,811,000 | 354,488,000 | 354,488,000 |

Balance notes

| | 2023 | 2022 | 2021 |
|----------------------------|---------|---------|---------|
| Accounting standard | IFRS | IFRS | IFRS |
| Employees | - | - | - |
| Equity ratio | 46.45% | 47.37% | 47.86% |
| Debt-equity ratio | 115.26% | 111.12% | 108.96% |

Others

| | 2023 | 2022 | 2021 |
|-------------------------|--------|-------|--------|
| Tax Expense Rate | 12.49% | 8.17% | 31.64% |

PHARMING GROUP N.V.

ISIN: NL0010391025 WKN: 518940 Asset Class: Stock

Income statement

| | 2023 | 2022 | 2021 |
|--|-------------|-------------|-------------|
| Turnover | 226,910,000 | 195,648,000 | 168,252,000 |
| Net income | -9,756,000 | 13,010,000 | 13,533,000 |
| EBIT | -8,591,126 | 20,407,730 | 24,125,601 |
| Operating income before taxes | -10,843,000 | 15,290,000 | 18,937,000 |
| Cash Flow | -19,546,000 | 17,348,000 | 27,857,000 |
| Net interest income | -2,252,000 | -5,117,000 | -5,187,000 |
| Research and development expenses | 60,144,000 | 48,458,000 | 56,868,000 |
| Income taxes | -1,354,000 | 1,249,000 | 5,991,000 |
| Result from investments in subsidiaries, associates and other | -267,000 | -1,030,000 | 587,000 |
| Revenues per employee | - | - | - |

Board of Directors

| | |
|----------------------------|-------------------------------|
| Richard Peters | Chairman of Supervisory Board |
| Jabine T. M. van der Meijs | Member of Supervisory Board |
| Mark Pykett | Member of Supervisory Board |
| Barbara Yanni | Member of Supervisory Board |
| Deborah Jorn | Member of Supervisory Board |
| Leonard Kruimer | Member of Supervisory Board |
| Steven Baert | Member of Supervisory Board |

Members of Management Board

| | |
|-----------------------|-------------------------------|
| Sijmen de Vries | Chairman of Managing Board |
| Alexander Breidenbach | Member of Executive Committee |
| Anurag Relan | Member of Executive Committee |
| Jeroen Wakkerman | Member of Executive Committee |
| Mireille Sanders | Member of Executive Committee |
| Ruud van Outersterp | Member of Executive Committee |
| Stephen Toor | Member of Executive Committee |